Skip to main content
SpringerLink
Log in

Gene-guided afatinib in advanced NSCLC: benefits at high cost

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • You R, et al. Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China. Cancer Management and Research : 5 Dec 2019. Available from: URL: https://doi.org/10.2147/CMAR.S219722

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gene-guided afatinib in advanced NSCLC: benefits at high cost. PharmacoEcon Outcomes News 843, 20 (2019). https://doi.org/10.1007/s40274-019-6447-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6447-8

Search

Navigation